The strategic reprioritization comes after Rocket Pharmaceuticals hit two major hurdles in the past year, including a clinical hold for an investigational gene therapy and an FDA rejection for its lead asset. #layoffs #fda #biotech #biospace https://xmrrwallet.com/cmx.phubs.ly/Q03yTP_c0
